PHAXIAM Therapeutics S.A. - ADR
PHXM
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.86M
Close$
$0.89
71.3% downside
Current Fair Value
71.3% downsideOvervalued by 71.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.86 Million |
|---|---|
| Enterprise Value | $20.30 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.62 |
| Beta | 1.8 |
| Outstanding Shares | 6,573,000 |
Return
| Return on Equity | -43.11% |
|---|---|
| Return on Assets | -21.52% |
| Return on Invested Capital | -42.67% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | 1.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.32 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.54 |
| Debt to Equity | 0.43 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PHAXIAM Therapeutics S.A.
181 employees
CEO: Gil Beyen founded in 2004, erytech is a biopharmaceutical company developing innovative therapies to target unmet medical needs, particularly in the fields of cancer and orphan diseases. erytech’s proprietary technology is based on encapsulation o...